Literature DB >> 18254715

Coenzyme Q10 and high-sensitivity C-reactive protein in ischemic and idiopathic dilated cardiomyopathy.

Mehmet Seneş1, Ali Riza Erbay, F Meriç Yilmaz, B Ciğdem Topkaya, Oğuzhan Zengi, Mehmet Doğan, Doğan Yücel.   

Abstract

BACKGROUND: Cardiomyopathy (CMP) is a common debilitating illness, associated with a high mortality and poor quality of life. There is extensive evidence from in vitro and animal experiments that CMP is a state of increased oxidative stress. Coenzyme Q10 (CoQ10) and high-sensitivity C-reactive protein (hs-CRP) are important markers to evaluate the oxidative stress and inflammatory status of patients with CMP.
METHODS: A total of 28 patients with chronic stable heart failure (21 men and 7 women, ages 18-76 years) were included in the study. Causes of heart failure were ischemic CMP in 17 patients and idiopathic dilated CMP in 11 patients. A total of 28 patients (12 men and 16 women; ages 30-71 years) with normal coronary angiography were enrolled as a control group. Levels of CoQ10, albumin, total thiol groups (T-SH), bilirubin, uric acid as plasma antioxidants, hs-CRP as an inflammation marker and lipid profile were studied in patients and controls.
RESULTS: Plasma CoQ10, T-SH and albumin levels were significantly decreased in patients compared to controls. Uric acid, bilirubin and hs-CRP levels were found to be significantly increased compared to controls.
CONCLUSIONS: In this study, evidence of decreased antioxidant status was determined in CMP patients together with vascular inflammation. CoQ10, other plasma antioxidants and hs-CRP measured routinely can reflect decreased antioxidant status and inflammatory process in patients with dilated CMP. These markers can be used to monitor the status of patients with CMP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18254715     DOI: 10.1515/CCLM.2008.061

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

1.  Coenzyme Q10 protects against acute consequences of experimental myocardial infarction in rats.

Authors:  Samy M Eleawa; Mahmoud Alkhateeb; Sanjoy Ghosh; Fahaid Al-Hashem; Abdullah S Shatoor; Abdulmohsen Alhejaily; Mohammad A Khalil
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2015-03-20

2.  Improved Health-Related Quality of Life, and More Days out of Hospital with Supplementation with Selenium and Coenzyme Q10 Combined. Results from a Double Blind, Placebo-Controlled Prospective Study.

Authors:  P Johansson; Ö Dahlström; U Dahlström; U Alehagen
Journal:  J Nutr Health Aging       Date:  2015-11       Impact factor: 4.075

3.  The effects of coenzyme Q10 supplementation on cardiometabolic markers in overweight type 2 diabetic patients with stable myocardial infarction: A randomized, double-blind, placebo-controlled trial.

Authors:  Seyyed Mehdi Mirhashemi; Vajiheh Najafi; Fariba Raygan; Zatollah Asemi
Journal:  ARYA Atheroscler       Date:  2016-07

Review 4.  Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem.

Authors:  Vladlena I Zozina; Serghei Covantev; Olga A Goroshko; Liudmila M Krasnykh; Vladimir G Kukes
Journal:  Curr Cardiol Rev       Date:  2018

5.  Coenzyme Q10 Reduces Infarct Size in Animal Models of Myocardial Ischemia-Reperfusion Injury: A Meta-Analysis and Summary of Underlying Mechanisms.

Authors:  Kamal Awad; Ahmed Sayed; Maciej Banach
Journal:  Front Cardiovasc Med       Date:  2022-04-15

6.  Effects of Coenzyme Q10 Supplementation on Oxidative Stress Markers, Inflammatory Markers, Lymphocyte Subpopulations, and Clinical Status in Dogs with Myxomatous Mitral Valve Disease.

Authors:  Natalia Druzhaeva; Alenka Nemec Svete; Gabrijela Tavčar-Kalcher; Janja Babič; Alojz Ihan; Katka Pohar; Uroš Krapež; Aleksandra Domanjko Petrič
Journal:  Antioxidants (Basel)       Date:  2022-07-22

Review 7.  Coenzyme Q10: Clinical Applications in Cardiovascular Diseases.

Authors:  Alma Martelli; Lara Testai; Alessandro Colletti; Arrigo F G Cicero
Journal:  Antioxidants (Basel)       Date:  2020-04-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.